Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAKUMI trial of osimertinib versus osimertinib plus carboplatin/pemetrexed in T790M-positive advanced non-small cell lung cancer after prior EGFR-TKI
jRCTs071180062Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib monotherapy with Osimertinib + carboplatin + pemetrexed (2 arms). Primary endpoint: progression-free survival. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180062.